Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
3
×
san diego top stories
san francisco blog main
san francisco top stories
startups
biogen
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vc
venture capital
wisconsin blog main
What
medicines
3
×
bio
covid
deal
ipo
new
roundup
acquisitions
activity
aiming
ambys
announced
approvals
big
biogen
biotech
ceo
clamped
collabs
control
daniel
deadly
debuted
delays
developing
diseases
economic
fast
fda
formed
future
gilead
gilead’s
help
including
introduce
isn’t
launch
liver
lot
Language
unset
Current search:
medicines
×
ipo
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
